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Synthetic analogues of marine alkaloid clathrodin
differently induce phosphatidylserine exposure in
monocytic cancer cells then in cancer stem cell
lines†‡
Dominik Nabergoj,§ab Sanja Vrbek,§ab Nace Zidar,a Tihomir Tomašić,a Danijel Kikelj,a
Lucija Peterlin Mašiča and Christian D. Muller*b
Activation of apoptosis in cancer cells could stop the development of several cancers. Through testing in
different human cancer cell lines (blood, liver, pancreas) and cancer stem cell lines (pancreas and testis), a
cytomic approach was performed to investigate kinetic differences in the mechanism of proapoptotic ac-
tivity induced by four synthetic analogues of clathrodin – an alkaloid isolated from Caribbean sea sponge.
Active on the tested cancer stem cell lines, analogue 5 interestingly shows a differential response in apo-
ptosis induction in the presence of pan caspase inhibitor Z-VAD-fmk in monocytic THP-1 cells. Thus in
monocytic cells, contrary to cancer stem cells, this caspase independent mechanism could reflect either a
scramblase modulation, a disturbed bidirectional trafficking of the membrane between the surface and cy-
toplasm or a necroptosis induction.
Introduction
Elucidating the mechanism of action of molecules inducing
apoptosis is an important step to understand the mecha-
nisms of resistance to any pro-apoptotic signal. Such resis-
tance facilitates the survival of pro-inflammatory cells favor-
ing the perpetuation of chronic inflammation and
furthermore the development of associated cancers.1 This
work is focused on understanding the activation of apoptosis
in cancer. Pharmacological tools, derived from marine alka-
loid clathrodin (MAREX project “Exploring Marine Resources
for Bioactive Compounds: From Discovery to Sustainable Pro-
duction and Industrial Applications 2010–2014” (www.marex.
fi) and COST Action CM1106) enabled us to study in detail an
original model of apoptosis induced anticancer activity. Our
results suggest that the induced phosphatidylserine (PS) exter-
nalization reflects trafficking of lysosomes to the cell surface2
rather than a simple enzymological process.3
Like some natural products, marine bioactive compounds
generally don't possess favorable physicochemical properties
and their structure has to be modified in order to obtain ana-
logues with improved potency, selectivity and favorable phar-
macokinetic properties.4 Clathrodin (1a) is a pyrrole-2-
aminoimidazole alkaloid (Fig. 1) isolated from the Caribbean
sea sponge Agelas clathrodes5 and is structurally related to its
brominated analogues oroidin (1b) from the sponge Agelas
oroides6,7 and hymenidin (1c) from the sponge Hymeniacidon
perlevis.8 A broad spectrum of reported bioactivities for ma-
rine alkaloids clathrodin, oroidin and hymenidin include
voltage-gated sodium channel blocking,9,10 antimicrobial,11
antihistaminic,12 antiserotoninergic,8 antimuscarinic,13 and
cytotoxic5 properties. Such a broad spectrum of biological ac-
tivities stimulated our interest in the design and synthesis of
libraries of analogues of marine alkaloids 1a–c14,15 and to
monitor their proapoptotic activities in human cancer cells of
different origins.
In a previous study,15 clathrodin, oroidin, hymenidin and
a library of 96 synthetic analogues from three structural fami-
lies were screened for their apoptosis inducing activities
against the human hepatocellular carcinoma HepG2 cell line.
Although the tested marine alkaloids were found to be only
weakly active, their most potent indole-based analogues 2–5,
obtained by rigidization in the central part of the parent alka-
loids and annelation of a phenyl ring to the pyrrole moi-
ety,16,17 exhibited EC50 values of 13–20 μM for HepG2 cell
line apoptosis induction and EC50 values of 20–24 μM for
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apoptosis induction in the acute monocytic leukemia THP-1
cell line. Through cell cycle analysis, we found that com-
pounds 2–5 induce apoptosis in THP-1 cells at 25 μM concen-
tration.15 These results stimulated us to perform a more com-
prehensive analysis of the mechanism of proapoptotic
activity of compounds 2–5 in different cancer phenotypes
(pancreas, liver and blood) and cancer stem cell lines (testis
and pancreas), an investigation presented herein. Time
course experiments revealed a different way of inducing
phosphatidylserine (PS) translocation onto the cell surface.
Thus, by activation of an enzyme part of the flippase family
e.g. the scramblase,3 compounds 2–5 could disturb bidirec-
tional trafficking of membrane components between the cell
surface and cytoplasm following a model where PS externali-
zation reflects Ca2+-mediated trafficking of many vesicles to
the cell surface.2
Materials and methods
Compounds 2–5
The clathrodin analogs 2,16 3,16 4 (ref. 16) and 5 (ref. 17) were
prepared as described by us previously. The purity of the
tested compounds was ≥95%.
Cell lines and culture conditions
NT2/D1 (CRL-1973), AsPC-1 (CRL-1682) and BJ (CRL-2522)
cell lines, all purchased from ATCC (LGC Standards,
Molsheim, France), were cultivated in physiological nutrient-
rich DMEM-based media (Sigma-Aldrich, Saint-Quentin-
Fallavier, France), supplemented with 10% (v/v) fetal bovine
serum (BioWhittaker, Verviers, Belgium), 2 mM glutamine,
50 μM non-essential amino acids, 50 U ml−1 penicillin and 50
μg ml−1 streptomycin (Sigma-Aldrich). THP-1 (TIB-202) and
BxPC-3 (CRL-1687) cells were grown in RPMI 1640 medium
with 2 mM L-alanyl-L-glutamine additionally supplemented
with 10% (v/v) fetal bovine serum, 50 U ml−1 penicillin and
50 μg ml−1 streptomycin (Sigma-Aldrich). HepG2 (HB-8065)
cell line was maintained in MEM media supplemented with
10% (v/v) fetal bovine serum, 50 U ml−1 penicillin, 50 μg ml−1
streptomycin (Sigma-Aldrich) and 2 mM glutamine. Prior to
treatment, cells were grown up to 80% confluency at 37 °C
under humidified atmosphere (5% CO2).
Cell treatment
Compounds 2–5 were diluted at 10 mM in DMSO and cells
were treated with appropriate working concentrations
premixed into cell culture medium. The highest concentra-
tion of DMSO (in treated and control cells) never exceeded
0.25% (v/v) to avoid any side effects, like toxicity or differenti-
ation induction. Experiments with the pan-caspase inhibitor
Z-VAD-FMK (obtained from BD Biosciences Pharmingen, San
Diego, CA, USA) were carried out according to the manufac-
turer's instructions.
Apoptosis rate analysis by annexin V binding assay
Revealing the externalization of phosphatidylserine and label-
ing the dead cell nucleus were used to assess apoptosis after
cells were cultured and treated or not with compounds 2–5.
Except for the non-adherent THP-1 cells, all other cell lines
were washed with PBS, trypsinized, centrifuged and re-
suspended in the first wash supernatant to preserve all non-
adherent apoptotic cells. A minimum of 2000 cells were ac-
quired and analyzed on InCyte (Guava/Millipore/Merck, CA,
USA). Apoptosis rates were assessed by capillary cytometry
(Guava EasyCyte Plus, Millipore Merck) after Annexin V-FITC
(ImmunoTools, Germany) and PI (MiltenyiBiotec Inc., USA)
labeling according to the manufacturer's recommendations.
Areas were drawn around single cell populations on forward
scatter (FSC) versus side scatter (SSC) dot plots so as to ex-
clude any debris. Cytometer performance was checked weekly
using the Guava easyCheck Kit 4500-0025 (Merck/Millipore/
Guava Hayward, CA, USA).
Cell cycle phase distribution analysis and quantification of
hypo diploid sub-G1 cell population
Cells were cultured at a density of 105–106 cells per ml
depending on the cell line, in accordance with ATCC's recom-
mendations. After 24 h, cells were incubated with com-
pounds 2–5 (25 μM) for different time periods in 6, 12, 24 or
96 well plates depending on the cell line phenotype. Then
Fig. 1 Clathrodin and synthetic analogs. Clathrodin (1a) is a pyrrole-2-aminoimidazole alkaloid from the Caribbean sea sponge Agelas clathrodes
structurally related to its brominated analogues hymenidin (1b) from the sponge Hymeniacidon perlevis and oroidin (1c) from the sponge Agelas
oroides. Indole-based analogues 2–5 are obtained by rigidization in the central part of the parent alkaloids and annelation of a phenyl ring to the
pyrrole moiety.
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cells were washed with PBS, re-suspended in 70% ethanol
and placed for 24 h at −20 °C. After centrifugation (5 min,
400g), cell pellets were washed twice with PBS then re-
suspended in 500 μl of PBS, incubated in FxCycle PI/RNase
Staining Solution (Life technologies, Thermo Fisher Scientific
Inc. USA) and kept in the dark at room temperature for 30
min. Cellular DNA content was then assessed by capillary cy-
tometry on a Guava EasyCyte Plus HP cytometer (EMD Milli-
pore Corporation, MA, USA). A minimum of 10 000 cells per
sample was acquired and analyzed on the InCyte software.
The percentage of cells in G0/G1, S, G2/M and sub-G1 was de-
termined from DNA content histograms.
Caspase-3/7 and caspases 8 and 9 activity determinations
Cells were cultivated as previously described. Apoptosis wash
buffer and caspase reagent working solution were prepared
according to the manufacturer's instructions (Merck Milli-
pore, Darmstadt, Germany). After 24 hours, cells were incu-
bated for different times with or without compounds 2–5 (25
μM). After trypsinization, except for non-adherent THP-1
cells, cells were collected by centrifugation and handled
according to the manufacturer's instructions (Merck Milli-
pore, Caspase 3/7 FAM, Caspase 9 SR, Caspase 8 FAM, Guava
Kits for Flow Cytometry). A minimum of 5000 cells was ac-
quired on the capillary cytometer then analyzed on InCyte.
Results
Apoptosis induction activities of clathrodin analogues 2–5
Previous results of proapoptotic activity in cancer cells of
several analogues of clathrodin15 lead us to test four best
performing compounds in additional human cancer and can-
cer stem cell (CSC) cell lines. Table 1 allows the comparison
of the EC50 values of the four analogues for apoptosis induc-
tion in different cell phenotypes. When considering CSCs of
testis (NT2/D1) or pancreatic origin (AsPC-1), micromolar
EC50 values were observed showing anticancer potency. For
other cancerous cell lines of pancreatic (BxPC-3), hepatic
(HepG2) or hematopoietic (THP-1) phenotype, similar poten-
cies were obtained to the non-cancerous human fibroblasts
cell line (BJ). All four analogs showed similar effectiveness
(EC50 values in the range of 11–16 μM) in NT2/D1 CSCs.
Among all the tested cell phenotypes, the monocytic THP-1
cell line was the one showing particularities in kinetic re-
sponsiveness, making our compounds original pharmacologi-
cal tools as further explained in the next paragraph.
Possessing a 2-(N-methylamino) imidazole moiety with no
Table 1 Clathrodin analogues apoptosis induction activitya
# Structure NT2/D1 AsPC-1 BxPC-3 HepG2 BJ THP-1
(2) 13 ± 5 27 ± 3 28 ± 4 13 ± 7 16 ± 6 23 ± 4
(3) 16 ± 8 19 ± 1 25 ± 3 16 ± 6 20 ± 3 24 ± 5
(4) 16 ± 1 52 ± 3 53 ± 12 18 ± 1 31 ± 17 20 ± 2
(5) 11 ± 2 32 ± 9 58 ± 14 20 ± 5 21 ± 9 24 ± 1
a Apoptosis was assessed by capillary cytometry, following Annexin V-FITC and PI labeling. For each sample, a minimum of 2000 cells (n = 3 in-
dependent experiments run in triplicate) was acquired and then analyzed on InCyte® allowing direct EC50 concentrations (μM) to be computed
from the cytograms. Cells were incubated with increasing concentrations (0.4–60 μM) of analogs as described under Materials and methods.
NT2/D1: CSCs of testis origin; AsPC-1: CSCs of pancreatic origin; BxPC-3: cancerous cell lines of pancreatic phenotype; HepG2: cancerous cell
lines of hepatic phenotype; THP-1: cancer cell lines of hematopoietic phenotype; BJ: non-cancerous human fibroblast cell line (THP-1 and
HEPG-2 data published previously15).
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Fig. 2 Time course response for proapoptotic activity of compound 5 on NT2/D1 and THP-1. These representative dot plots were obtained after
time-dependent treatment with compound 5 [25 μM] of NT2/D1 and THP-1 cells. Cells were labeled with Annexin V (green fluorescence (GRN-
HLog))/PI (red fluorescence (RED-HLog)) as described under Materials and methods. The numbers indicated in each quadrant represent the differ-
ent apoptotic states expressed as % of the total cell number (2000 events per sample).
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substitution in the indole ring and displaying a suitable
proapoptotic activity on NT2/D1 cancer stem cells (ED50 = 11
± 2 μM), compound 5 was chosen for further mechanistic ex-
periments on NT2/D1 CSC and THP-1 cell lines.
Differential activity of compound 5 on monocytic cancer
phenotype
Time course experiments (Fig. 2) indicate that after 3 hours,
compound 5 was able to induce 17% of THP-1 cells to die
by apoptosis when only 3% of NT2/D1 were affected (cells in
the upper right quadrant). If after 5 hours this percent
was doubled, after 7 hours, 4 times more THP-1 cells were
dead. This kinetic difference suggests a divergence in tar-
gets involved in cell death for THP-1 cells, considering all
other tested cell types were responding as the NT2/D1 phe-
notype (results for the other cell types not shown). With
THP-1 cells being of immune phenotype, necroptosis is a
possible mechanism to be involved here, as it is character-
ized as a component of inflammatory diseases when im-
mune cells undergo “cellular suicide”.18,19 Thus, further ex-
periments done in the presence of a pan-caspase inhibitor
should help us to understand these kinetic dissimilarities
in PS externalization.19
Compound 5 induces sub-G1 population in both THP-1 and
NT2/D1 cells
If an increased number of hypodiploid sub-G1 cells can be
observed when teratocarcinomal cancer stem-like cells NT2/
D1 and monocytic cells THP-1 are exposed to compound 5,
death by apoptosis cannot be excluded as the cellular DNA
content is reduced even if kinetic response profiles are differ-
ent to extracellular PS exposure previously demonstrated in
Fig. 2 by accumulation of cells in the upper right quarter of
the cytograms (PS + PI positives cells). Induction of DNA frag-
mentation was observed in both cell lines (Fig. 3) with, this
time, no kinetic distinctions. Even a delay for THP-1 DNA
fragmentation was noticeable when compared to the fast re-
sponse rate for PS exposure (see Fig. 2).
Fig. 3 Cell cycle analyses for proapoptotic activity of compound 5 on NT2/D1 and THP-1. Cell cycle distribution was assessed by capillary
cytometry. This figure shows representative time course of DNA content histograms (10000 events per sample) for (A) NT2/D1 and (B) THP-1 cell
in the presence of 25 μM of compound 5. (C) and (D) recapitulate for each cell line, in a bar graph format, the distribution in sub-G1, G0/G1, S or
G2/M phases; the number of cells in each mitosis phase was computed and expressed as % of the total cellular population.
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Compound 5 induces apoptosis in cancer stem-like cells and
monocytic cells via a caspase-dependent mechanism
According to the biochemical classification of cell death, apo-
ptosis can be divided, due to different mechanistic pathways,
into extrinsic and intrinsic apoptosis.20 Extrinsic apoptosis is
potentially coupled with intrinsic apoptosis since caspase
8 activation can also cleave and activate pro-apoptotic protein
Bid and cause permeabilization of the mitochondrial outer
membrane, which in turn activates caspase 9 and later on
also caspases 3/7.21 Activation of caspases 3/7, one of the
most significant apoptotic effector caspases, leads to final ex-
ecution of apoptotic cell death since activated caspase 3 acti-
vates caspase-activated DNase (CAD) which causes fragmenta-
tion of DNA and chromatin condensation. Furthermore,
caspase 3 is also responsible for reorganization of cytoskele-
ton and formation of apoptotic bodies. Data in Fig. 4 shows
activation of caspases 3/7 in NT2/D1 and THP-1 cell lines,
starting already after 3 hours of incubation with compound
5, as expected by detection of DNA fragmentation. Caspase
8 activation was observed prior to activation of caspase 9, in-
dicating that the extrinsic pathway is activated in both cell
lines (Fig. 4). Again, no kinetic differences were observed
here between the two cell lines. We further examined the ef-
fects of a caspase inhibitor on proapoptotic activity in terato-
carcinoma cells.
Compound 5 induces PS exposure in monocytic cells via a
caspase-independent mechanism
As shown in Fig. 5, the pan-caspase inhibitor Z-VAD-FMK was
able to fully countervail the exposure of PS in NT2/D1 cancer
stem cells: after 4 hours, only a few cells migrated to the
quarters of the cytograms, where PS + PI positive cells accu-
mulate. On the contrary, annexin V was able to stain 82% of
THP-1 cells after the same time period as all the cells
remained in the right part of the cytogram. Knowing that
necroptosis is a well-defined viral defense mechanism which
Fig. 4 Time-dependent induction of caspase activities by compound 5 in NT2/D1 and THP-1 cells. Time dependent induction of caspases 3/7 by
analogue 5 was observed in accordance with DNA fragmentation seen in Fig. 4. Caspase 8 (-○-) and caspase 9 (-□-) differential activation was also
monitored for both cell lines in the presence of analog 5. Left panels present graphs obtained for the NT2/D1 cell line and right panels for THP-1
cells, respectively. Cells were incubated with analog 5 [25 μM] for different time points and caspase 3/7 or caspase 8 and 9 activities were moni-
tored as described under Materials and methods. Dead cells were excluded using 7-AAD staining and activated caspases were detected as a time-
dependent increase of mean fluorescence intensity per cell (tests run in duplicate, 5000 events per sample).
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Fig. 5 Different behaviors of the pan caspase inhibitor Z-VAD-fmk in NT2/D1 and THP-1 cells. Representative dot plots obtained after 4 hours of
treatment of NT2/D1 and THP-1 cells with or without compound 5 [25 μM] in the presence or absence of the pan caspase inhibitor Z-VAD-fmk [50
μM]. Cells were labeled with Annexin V/PI as described under M&M (n = 3 independent experiments run in triplicate, 5000 events per sample were
analyzed).
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allows the cell to undergo “cellular suicide” in a caspase-
independent fashion in the presence of viral caspase inhibi-
tors, this mechanism could be induced by compound 5.22 In
addition to being a response to disease, necroptosis has also
been characterized as a component of inflammatory dis-
eases.25 Thus, the activity of compound 5 on monocytic THP-
1 cells specifically is plausible, as NT2/D1 cells are not of im-
mune phenotype.
Discussion
Marine natural products are a valuable source of bioactive
compounds, which can be used as leads for drug discovery in
various therapeutic areas.23 However, like other natural prod-
ucts, marine bioactive compounds are complex in structure
and generally don't possess favorable physicochemical prop-
erties. Their structure generally needs to be modified in order
to obtain synthetically tractable analogues with improved po-
tency, selectivity and improved pharmacokinetic properties.4
Following these principles, the results of testing our library
of conformationally restricted clathrodin analogues for
proapoptotic activity in HepG2 and THP-1 cancer cells15 lead
us to test four most potent analogues on additional human
cancer (BxPC3) and cancer stem cell (NT2/D1, AsPC-1)
models. Comparison of the four analogs for their respective
EC50 values on human cells of different phenotypes (Table 1)
failed to highlight one of them. Compound 5 bearing no sub-
stituent on the indole ring was chosen for a deeper mecha-
nistic study and kinetic experiments were carried out in order
to pick the most sensitive cancer phenotype. Among all tested
cell phenotypes, the monocytic THP-1 cell line was the only
one reacting in less than 5 hours to analog 5 (Fig. 2). After 5
hours of incubation with compound 5, at a 25 μM concentra-
tion equivalent to the EC50 for THP-1 cells, 38% of the cells
died by apoptosis. On the other hand on the same time scale,
only 6% of NT2/D1 cells were affected. Such kinetic dissimi-
larities suggest different targets involved in THP-1 cell death,
bearing in mind that all other tested cell phenotypes were
responding like NT2/D1 (data not shown). Apoptosis in-
creases the number of hypodiploid sub-G1 cell population, so
that an equivalent kinetic profile should have been acquired
for 24 hours. The results obtained (Fig. 3) did not confirm a
quicker response for THP-1 phenotype; even a slight delay in
response was identified. Is such a delay imputable to a differ-
ence in the caspase cascade response? But neither for
caspase 3/7 nor caspase 8 or caspase 9 could a faster re-
sponse be observed (Fig. 4). Only the presence of the pan-
caspase inhibitor Z-VAD-FMK did help to further decipher
the mechanism involved (Fig. 5). In 4 hours, the pan caspase
inhibitor Z-VAD-fmk was not able to prevent THP-1 annexin-V
positive cells; the sum of the lower and upper right quad-
rants was 82%, a value close to the 95% observed in the ab-
sence of an inhibitor. On the contrary, in NT2/D1 cells, apo-
ptosis was hindered as only 11% cells presented PS at their
surface (vs. 29% in the absence of an inhibitor). It was dem-
onstrated earlier24 that activated caspases inhibit PS flippase
during apoptosis, thus blocking the transport of PS from the
extra-cellular to the cytoplasmic side imposing PS to stay out-
side. Furthermore, as recently stated,3 scramblase is involved
in the first state of activation during apoptosis, then flippase
is inactivated to induce all PS to stay outside. Considering
the results obtained in the presence of the pan-caspase inhib-
itor Z-VAD-fmk, one could assume scramblase to be the tar-
get of analog 5. But for the NT2/D1 cell line, the cell surface
PS induced by compound 5 is highly reduced by the action of
the caspase inhibitor, indicating that, for that cellular pheno-
type, the transport of PS from the extra-cellular to the cyto-
plasmic side is still effective even in the case of an activated
scramblase. For the THP-1 cells, in the presence of com-
pound 5 and the caspase inhibitor Z-VAD-fmk, PS is highly
present outside the cells indicating that in the presence of
the studied clathrodin analogs, PS extracellular exposure is
really dependent on the cellular phenotype. As mentioned
earlier, a necroptosis induction could be involved here.
Necroptosis is a programmed cell death pathway recently
identified by Degterev et al.25 Necroptosis is a viral defense
mechanism allowing the cell to undergo “cellular suicide” in
a caspase-independent fashion in the presence of viral
caspase inhibitors.25 The clathrodin analogues could also dis-
turb bidirectional trafficking of the membrane between the
cell surface and cytoplasm following the model of Lee, S. H.
and colleagues, where PS externalization reflects Ca2+-medi-
ated trafficking of many vesicles to the cell surface.2 These
authors suggest that apoptotic PS externalization results from
a two-step process that begins with the internalization of the
plasma membrane as cells shrink during apoptosis, forming
intracellular vesicles that are then trafficked back to the cell
surface in a Ca2+-dependent manner. According to their new
model for PS externalization during apoptosis, they identified
an altered step that could as well be applied for caspase inde-
pendent apoptotic PS exposure when compared to the CSC
cell line NT2/D1.
The original results described therein with a new set of
clathrodin analogues demonstrate that in a monocytic cancer
phenotype, PS exposure can be a caspase independent mech-
anism. Caspase-independent PS exposure was described ear-
lier in primary T cells during apoptosis induced by stimuli
that do not trigger death receptors.26 Today different ways of
action can be supported. The first is the one suspected by S.
Nagata3 as the scramblase activity seems highly involved in
the monocytic cell lineage. Secondly, again in accordance
with monocytic cellular phenotype, intracellular vesicles traf-
ficking back to the cell surface can be involved if one follows
the model of Lee, S. H. and colleagues2 so that further stud-
ies are needed to distinguish between these two models.
Thirdly, necroptosis induction in THP-1 cells cannot be ex-
cluded. Thus apoptotic PS externalization induced by
clathrodin analogue 5 on blood cancer cells could result from
a caspase independent mechanism specific to monocytic cell
lineage and reflect either scramblase modulation, disturbed
bidirectional trafficking of the membrane between the cell
surface and cytoplasm or necroptosis induction, highlighting
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analogue 5 as an interesting new pharmacological tool. In
summary, the presented results permitted the discovery of a
new set of clathrodin analogs with pro-apoptotic activities on
different cancer stem cells (NT2/D1, AsPC-1 and BxPC-3) with
differential kinetic properties on immune cells (THP-1).
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